Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.
van Helden MJ, Zwarthoff SA, Arends RJ, Reinieren-Beeren IMJ, Paradé MCBC, Driessen-Engels L, de Laat-Arts K, Damming D, Santegoeds-Lenssen EWH, van Kuppeveld DWJ, Lodewijks I, Olsman H, Matlung HL, Franke K, Mattaar-Hepp E, Stokman MEM, de Wit B, Glaudemans DHRF, van Wijk DEJW, Joosten-Stoffels L, Schouten J, Boersema PJ, van der Vleuten M, Sanderink JWH, Kappers WA, van den Dobbelsteen D, Timmers M, Ubink R, Rouwendal GJA, Verheijden G, van der Lee MMC, Dokter WHA, van den Berg TK. van Helden MJ, et al. Among authors: ubink r. J Immunother Cancer. 2023 Apr;11(4):e006567. doi: 10.1136/jitc-2022-006567. J Immunother Cancer. 2023. PMID: 37068796 Free PMC article.
Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody-Drug Conjugate.
Groothuis PG, Jacobs DCH, Hermens IAT, Damming D, Berentsen K, Mattaar-Hepp E, Stokman MEM, Boekel TV, Rouwette M, van der Vleuten MAJ, Sesink A, Dijcks FA, Coumans RGE, Schouten J, Glaudemans DH, Wijk DV, Blomenröhr M, Kappers WA, Ubink R, van der Lee MMC, Dokter WHA. Groothuis PG, et al. Among authors: ubink r. Mol Cancer Ther. 2023 Jun 1;22(6):765-777. doi: 10.1158/1535-7163.MCT-22-0596. Mol Cancer Ther. 2023. PMID: 37042205 Free PMC article.
Discovery of SYD5115, a novel orally active small molecule TSH-R antagonist.
Karstens WFJ, M B P Menge W, Martens G, Op Het Veld SJN, Th H van Eupen J, Demon M, van Achterberg TAE, Arisse-Thijssen MJ, Santegoeds-Lenssen EWH, van der Lee MMC, Ubink R, Arends RJ, Sesink A, Blomenröhr M, Marco Timmers C. Karstens WFJ, et al. Among authors: ubink r. Bioorg Med Chem. 2023 Apr 15;84:117258. doi: 10.1016/j.bmc.2023.117258. Epub 2023 Mar 23. Bioorg Med Chem. 2023. PMID: 37001244 Free article.
A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines.
Coumans RGE, Ariaans GJA, Spijker HJ, Renart Verkerk P, Beusker PH, Kokke BPA, Schouten J, Blomenröhr M, van der Lee MMC, Groothuis PG, Ubink R, Dokter WHA, Timmers CM. Coumans RGE, et al. Among authors: ubink r. Bioconjug Chem. 2020 Sep 16;31(9):2136-2146. doi: 10.1021/acs.bioconjchem.0c00337. Epub 2020 Aug 25. Bioconjug Chem. 2020. PMID: 32697078
Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice.
Ubink R, Dirksen EHC, Rouwette M, Bos ES, Janssen I, Egging DF, Loosveld EM, van Achterberg TA, Berentsen K, van der Lee MMC, Bichat F, Raguin O, van der Vleuten MAJ, Groothuis PG, Dokter WHA. Ubink R, et al. Mol Cancer Ther. 2018 Nov;17(11):2389-2398. doi: 10.1158/1535-7163.MCT-18-0329. Epub 2018 Aug 9. Mol Cancer Ther. 2018. PMID: 30093567
Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán Buitrago MA, Nagelkerke SQ, Németh I, Ubink R, Rouwendal G, Lohse S, Valerius T, Leusen JH, Boross P. Brandsma AM, et al. Among authors: ubink r. Cancer Immunol Res. 2015 Dec;3(12):1316-24. doi: 10.1158/2326-6066.CIR-15-0099-T. Epub 2015 Sep 25. Cancer Immunol Res. 2015. PMID: 26407589
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Elgersma RC, Coumans RG, Huijbregts T, Menge WM, Joosten JA, Spijker HJ, de Groot FM, van der Lee MM, Ubink R, van den Dobbelsteen DJ, Egging DF, Dokter WH, Verheijden GF, Lemmens JM, Timmers CM, Beusker PH. Elgersma RC, et al. Among authors: ubink r. Mol Pharm. 2015 Jun 1;12(6):1813-35. doi: 10.1021/mp500781a. Epub 2015 Feb 18. Mol Pharm. 2015. PMID: 25635711
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.
van der Lee MM, Groothuis PG, Ubink R, van der Vleuten MA, van Achterberg TA, Loosveld EM, Damming D, Jacobs DC, Rouwette M, Egging DF, van den Dobbelsteen D, Beusker PH, Goedings P, Verheijden GF, Lemmens JM, Timmers M, Dokter WH. van der Lee MM, et al. Among authors: ubink r. Mol Cancer Ther. 2015 Mar;14(3):692-703. doi: 10.1158/1535-7163.MCT-14-0881-T. Epub 2015 Jan 14. Mol Cancer Ther. 2015. PMID: 25589493
31 results